SAB Biotherapeutics (SABS) Interest Expenses (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Interest Expenses came in at $27.6 million in Q1 2026, up 10453.66% YoY from N/an in Q1 2025, and up 44109.37% on a QoQ basis from $62331.0 in Q4 2025.
SAB Biotherapeutics (SABS) Interest Expenses (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Interest Expenses data on file, last reported at $27.6 million in Q1 2026.
- Quarterly Interest Expenses rose 10453.66% year-over-year to $27.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.6 million (up 10453.66% YoY) and the FY2025 annual result came in at $26.1 million, up 2098.01% from the prior year.
- Interest Expenses grew to $27.6 million in Q1 2026, from $62331.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $27.6 million in Q1 2026 to a low of -$636608.0 in Q4 2022.
- A 5-year average of $2.0 million and a median of $261105.0 in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses slumped 1060.56% — and 2026, when it soared 10453.66%.
- Tracing SABS's Interest Expenses over 5 years: stood at -$636608.0 in 2022, then surged by 112.23% to $77879.0 in 2023, then plunged by 482.7% to -$298046.0 in 2024, then surged by 120.91% to $62331.0 in 2025, then surged by 44109.37% to $27.6 million in 2026.
- The last three Interest Expenses figures came in at $27.6 million (Q1 2026), $62331.0 (Q4 2025), and $728650.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 29.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.10 Mn |
| Jun 30, 2026 | 29.10 Mn |
| Mar 31, 2026 | 27.56 Mn |
| Mar 31, 2026 | 27.56 Mn |
| Dec 31, 2025 | 62,331.00 |
| Dec 31, 2025 | 62,331.00 |
| Sep 30, 2025 | 728,650.00 |
| Sep 30, 2025 | 728,650.00 |
| Jun 30, 2025 | 728,650.00 |
| Jun 30, 2025 | 728,650.00 |
| Mar 31, 2025 | 261,105.00 |
| Mar 31, 2025 | 261,105.00 |
| Dec 31, 2024 | -298,046.00 |
| Dec 31, 2024 | -298,046.00 |
| Sep 30, 2024 | 261,000.00 |
| Sep 30, 2024 | 261,000.00 |
| Jun 30, 2024 | 246,000.00 |
| Jun 30, 2024 | 246,000.00 |
| Mar 31, 2024 | 236,105.00 |
| Mar 31, 2024 | 236,105.00 |